Us Congress House Bill HB2450

Us Congress 2025-2026 Regular Session

• Introduced: 3/27/25
• Refer: 3/27/25

Caption

Prescription Drug Transparency and Affordability Act

Impact

The proposed legislation is expected to substantially impact state laws regarding health insurance and pharmacy benefit management, fostering a more transparent environment that could ultimately lower costs for consumers. Health plans will be required to disclose intricate details about their prescription drug coverage, which may reveal discrepancies between drug costs at different pharmacies and the actual amounts paid by patients versus what the insurers report. This potential for increased transparency is intended to facilitate informed decision-making among patients and lead to competitive pricing among pharmacies.

Summary

House Bill 2450, known as the Prescription Drug Transparency and Affordability Act, proposes a series of amendments to enhance oversight of pharmacy benefit management (PBM) services, addressing transparency in the costs and processes related to prescription drugs. The bill mandates that group health plans and health insurance issuers provide detailed reports concerning the costs associated with drugs dispensed, including contracted compensation, rebates, and out-of-pocket expenses for participants. By ensuring clear, accessible disclosure, the bill aims to empower patients and employers with insights into their prescription medication costs and overall health plan spending.

Contention

While HB 2450 is aimed at increasing accountability among pharmaceutical benefit managers and health insurers, the bill has not been without contention. Supporters argue that it addresses a critical need for greater transparency in an industry often criticized for its obscured pricing and complex rebate structures. However, opponents are concerned that the added regulatory burden placed on health care providers and payers could lead to increased administrative costs, which might inadvertently be passed down to consumers. Additionally, some fear that the bill might not effectively address the root causes of high drug prices, with debates centered around whether transparency alone is sufficient to mitigate these persistent issues.

Congress_id

119-HR-2450

Policy_area

Health

Introduced_date

2025-03-27